Table 5.
Sample ID | Idylla™ | Therascreen | Confirmatory result | Reference approach | VAF (%) |
---|---|---|---|---|---|
S8470 | A146P/T/V | N/A | A146T | MPS | 31 |
S8476 | A146P/T/V | N/A | A146T | MPS | 20 |
S8342 | A146P/T/V | N/A | A146V | MPS | 2 |
S9195 | A146P/T/V | N/A | A146T | MPS | 30 |
S8426 | A146P/T/V | 12VAL | A146V | Sanger | N/A |
S8383 | A146P/T/V | N/A | A146T | Sanger | N/A |
S8397 | K117N | 12CYS | K117N | Sanger | N/A |
S8250 | K117N | N/A | Q61K | MPS | 23 |
S8475 | K117N | N/A | K117N | MPS | 70 |
S8431 | A59T/E/G | N/A | No mutation detected | MPS | N/A |
S8233 | Q61H | N/A | Q61H | Sanger | N/A |
S8377 | Q61H | N/A | Q61H | Sanger | N/A |
S8956 | Q61H | N/A | Q61H | MPS | 42 |
S8494 | G12V | 12SER | G12V | MPS | 37 |
S8546 | G13D | 12SER | G12C | MPS | 33 |
Confirmatory testing of Idylla results using massive parallel sequencing (MPS) or Sanger Sequencing. Samples 1–13 were discordant-by-design mutations and Samples 14–15 were mutant-mutant discordants. Samples 1–13 were not taken into account for agreement calculations